Commerce Bank boosted its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 9.8% in the first quarter, Holdings Channel.com reports. The fund owned 7,790 shares of the biopharmaceutical company’s stock after acquiring an additional 695 shares during the quarter. Commerce Bank’s holdings in Regeneron Pharmaceuticals were worth $3,804,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Capital Analysts LLC boosted its holdings in Regeneron Pharmaceuticals by 12.6% during the 1st quarter. Capital Analysts LLC now owns 490 shares of the biopharmaceutical company’s stock valued at $239,000 after acquiring an additional 55 shares during the period. Alberta Investment Management Corp grew its stake in Regeneron Pharmaceuticals by 21.7% during the 1st quarter. Alberta Investment Management Corp now owns 25,241 shares of the biopharmaceutical company’s stock worth $12,325,000 after buying an additional 4,501 shares during the last quarter. ETRADE Capital Management LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth $336,000. Ariose Capital Management Ltd purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth $1,953,000. Finally, Dai Ichi Life Insurance Company Ltd grew its stake in Regeneron Pharmaceuticals by 93.5% during the 1st quarter. Dai Ichi Life Insurance Company Ltd now owns 9,313 shares of the biopharmaceutical company’s stock worth $4,547,000 after buying an additional 4,500 shares during the last quarter. Institutional investors own 66.58% of the company’s stock.
In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 214 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $449.01, for a total transaction of $96,088.14. Following the completion of the transaction, the chief financial officer now owns 25,973 shares of the company’s stock, valued at $11,662,136.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director George L. Sing sold 850 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $575.00, for a total value of $488,750.00. Following the transaction, the director now directly owns 120,415 shares of the company’s stock, valued at approximately $69,238,625. The disclosure for this sale can be found here. Insiders have sold 196,397 shares of company stock valued at $109,206,506 in the last three months. Insiders own 11.84% of the company’s stock.
NASDAQ REGN opened at $569.91 on Friday. The stock has a market capitalization of $61.72 billion, a price-to-earnings ratio of 28.64, a PEG ratio of 1.23 and a beta of 0.53. Regeneron Pharmaceuticals Inc has a twelve month low of $271.37 and a twelve month high of $583.54. The company has a current ratio of 4.21, a quick ratio of 3.49 and a debt-to-equity ratio of 0.06. The stock has a 50-day moving average of $541.71 and a 200 day moving average of $427.59.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $6.60 earnings per share for the quarter, topping analysts’ consensus estimates of $6.13 by $0.47. The company had revenue of $1.83 billion during the quarter, compared to analysts’ expectations of $1.81 billion. Regeneron Pharmaceuticals had a return on equity of 24.94% and a net margin of 28.56%. Regeneron Pharmaceuticals’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.45 EPS. Equities analysts predict that Regeneron Pharmaceuticals Inc will post 23.84 EPS for the current fiscal year.
REGN has been the topic of several research analyst reports. Canaccord Genuity boosted their target price on Regeneron Pharmaceuticals from $575.00 to $630.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Royal Bank of Canada dropped their target price on Regeneron Pharmaceuticals from $533.00 to $524.00 in a research note on Wednesday, May 6th. Oppenheimer boosted their price target on Regeneron Pharmaceuticals from $525.00 to $625.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. BidaskClub upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, May 7th. Finally, SunTrust Banks boosted their price target on Regeneron Pharmaceuticals to $400.00 and gave the company a “hold” rating in a research note on Friday, February 7th. Fourteen analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $515.26.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Article: G-20
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.